Search
argenx SE
ARGXAdd to Watchlist
782.170USD
-5.140-0.65%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
49.16BMarket Cap
32.32P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-0.65%
5 Days
-0.17%
1 Month
-2.29%
6 Months
-8.48%
Year to Date
-6.99%
1 Year
+42.30%
TradingKey Stock Score of argenx SE
Currency: USD Updated: 2026-05-08Key Insights
argenx SE's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 120 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1037.03.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
argenx SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
argenx SE Highlights
StrengthsRisks
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 238.52% year-on-year.
Fairly Valued
The company’s latest PE is 32.32, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 30.31M shares, decreasing 10.27% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 117.00 shares of this stock.
Analyst Rating
Based on
26
analysts
Buy
Current Rating
1035.942
Target Price
+31.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
argenx SE News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
argenx SE Info
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Ticker SymbolARGX
Companyargenx SE
CEOvan Hauwermeiren (Tim)
Websitehttps://www.argenx.com/
Related Instruments
-2.75%
-0.53%
-0.67%
+0.54%
+0.20%
-0.82%
+0.79%
-2.04%
+0.61%
-1.48%
-0.14%
+1.13%
+0.30%
-0.20%
-2.42%
+0.82%
0.00%
-1.05%
-0.86%Popular Instruments
92.193
-2.977 (-3.13%)
293.320
+5.817 (+2.02%)
215.200
+3.717 (+1.76%)
4714.280
+29.030 (+0.62%)
480.000
+16.095 (+3.47%)
1562.340
+222.380 (+16.60%)
746.810
+100.160 (+15.49%)
400.800
+2.723 (+0.68%)
80959.990
+184.490 (+0.23%)
428.350
+16.560 (+4.02%)
